PTCT — PTC Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $3.38bn
- $4.76bn
- $937.82m
- 41
- 36
- 83
- 52
Annual income statement for PTC Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 307 | 381 | 539 | 699 | 938 |
| Cost of Revenue | |||||
| Gross Profit | 295 | 362 | 506 | 654 | 872 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 548 | 813 | 913 | 1,146 | 1,515 |
| Operating Profit | -241 | -432 | -374 | -447 | -577 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -240 | -403 | -518 | -587 | -696 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -252 | -438 | -524 | -559 | -627 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -252 | -438 | -524 | -559 | -627 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -252 | -438 | -524 | -559 | -627 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.27 | -6.53 | -7.43 | -7.49 | -5 |